Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital of Philadelphia
• Collaborator: University of Pennsylvania
• Treatments: Dihydroxyphenylalanine

Criteria

Inclusion Criteria:

• Any age, but primarily infants 0-6 months.

• Children with confirmed diagnosis of congenital hyperinsulinism.

Exclusion Criteria:

• Cases in which surgery will not be considered by parents or guardians.